Invest Europe
Success stories: VC at the heart of life sciences summary video
Videos
0:39
•
13 Oct 2022
New Invest Europe report highlights venture capital’s role in supporting pioneering European life sciences start-ups.
The new study shines a light on investment and employment in the sector at the heart of public health in Europe, and presents a large library of case studies of Biotech start-ups breaking new ground in the fight against cancer and other life-threatening conditions.
Venture capital firms backed 2,634 start-ups with €13.5 billion of capital over five years to the end of 2021, accounting for almost 25% of all VC investment. VC investment in European Life Sciences increased for ten successive years from 2012, rising four-fold to €3.9 billion in 2021.All private equity and venture capital backed Biotech & Healthcare companies in Europe employed almost 1.3 million people in 2020. The late-stage VC segment employed 56,867 people and was one of the fastest growing, increasing employment by 20% between 2019 and 2020.The digital report combines comprehensive Invest Europe data with real-life studies into European start-ups past and present that are reshaping the Life Sciences sector across the continent. It presents a wide-ranging library of case studies, covering segments from Biotechnology Therapeutics and Medical Devices to Diagnostics and Digital Health, to demonstrate the power of venture capital investment and expertise in the fight to save lives and improve health outcomes for millions of people in Europe and across the globe.
